Low serum concentration of sulfatide and presence of sulfated lactosylceramid are associated with Type 2 diabetes. The Skaraborg Project

Diabetic Medicine

Volumn 22, Issue 9, 2005, Pages 1190-1198

  Buschard, K ^a   Fredman, P ^b   Bog Hansen E ^c,d   Blomqvist, M ^b   Hedner, J ^b   Rastam L ^c   Lindblad, Ulf ^c,e  

^a Rigshospitalet   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Skaraborgs Institutet   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Insulin resistance; Sulf lac cer sulfatide; Sulfated lactosylceramide; Type 2 diabetes

Indexed keywords

GLYCOSPHINGOLIPID; INSULIN; LACTOSYLCERAMIDE; POTASSIUM CHANNEL; SULFATIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXOCYTOSIS; FEMALE; GENDER; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RISK FACTOR; SECRETORY GRANULE; SEX DIFFERENCE;

ANTIGENS, CD; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GALACTOSYLCERAMIDES; HUMANS; INSULIN RESISTANCE; LACTOSYLCERAMIDES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SEX DISTRIBUTION; SULFOGLYCOSPHINGOLIPIDS; SWEDEN;

EID: 24044504407     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01613.x     Document Type: Article

References (34)

1. Fredman P, Mattsson L, Andersson K, Davidsson P, Ishizuka I, Jeansson S et al. Characterization of the binding epitope of a monoclonal antibody to sulfatide. Biochem J 1988; 1: 17-22.
2. Fredman P, Mansson JE, Rynmark BM, Josefsen K, Ekblond A, Halldner L et al. The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling: possible involvement in insulin trafficking. Glycobiology 2000; 10: 39-50.
3. Osterbye T, Jørgensen KH, Fredman P, Tranum-Jensen J, Kaas A, Brange J et al. Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 2001; 11: 473-479.
4. Buschard K, Høy M, Bokvist K, Olsen HL, Madsbad S, Fredman P et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K+-channel activity and Ca2+-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002; 51: 2514-2521.
5. Blomqvist M, Kaas A, Mansson JE, Formby B, Rynmark BM, Buschard K et al. Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosyl ceramide expression in mammalian pancreas. J Cell Biochem 2003; 89: 301-310.
6. Otonkoski T, Andersson S, Knip M, Simell O. Maturation of insulin response to glucose during human fetal and neonatal development. Diabetes 1988; 37: 286-291.
7. Zimmet P. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from the west to the rest. Diabetes Care 1992; 15: 232-252.
8. Tuomilehto J, Tuomilehto-Wolf E, Zimmet P, Alberti K, Knowler W. Primary prevention of diabetes mellitus. In Alberti K, Zimmet P, DeFronzo R, Keen H eds. International Textbook of Diabetes Mellitus. Chichester, UK: Johan Wiley, 1997: 1799-1827.
9. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
10. Martin B, Warram J, Krolewski A, Bergman R, Soeldner S, Kahn R. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340: 925-929.
11. Bøg-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project. J Int Med 1998; 243: 223-232.
12. Östgren CJ, Lindblad U, Bøg-Hansen E, Ranstam J, Melander A, Råstam L. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes. The Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab 1999; 1: 105-112.
13. Råstam L, Berglund G, Isacsson S-O, Rydén L. The Skaraborg Hypertension Project. II. Feasibility of a medical care program for hypertension. Acta Med Scand 1986; 219: 249-260.
14. Råstam L, Berglund G, Isacsson S-O, Rydén L. The Skaraborg Hypertension Project. III. Influence on blood pressure of a medical care program for hypertension. Acta Med Scand 1986; 219: 261-269.
15. Lindblad U, Råstam L, Rydén L, Ranstam J, Berglund G, Isacsson S-O. Reduced stroke incidence with structured hypertension care: The Skaraborg Hypertension Project. J Hypertens 1990; 8: 1147-1153.
16. Bøg-Hansen E, Lindblad U, Ranstam J, Melander A, Råstam L. Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension. Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab 2001; 3: 25-31.
17. Spooren PF, Lekkerkerker JF, Vermes I. Micral-Test: a qualitative dipstick test for microalbuminuria. Diabetes Res Clin Pract 1992; 18: 83-87.
18. Eckerbom S, Bergqvist Y, Jeppson JO. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994; 31: 355-360.
19. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 38: 578-582.
20. Råstam L, Sjönell G. A new device for measuring blood pressure in adults. Lancet 1991; 337: 249-250.
21. World Health Organization Expert Committee. Diabetes Mellitus. Technical Report series no. 742. Geneva: WHO, 1985.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
23. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-822.
24. Fukushima M, Taniguchi A, Sakai M, Doi K, Nagasaka S, Tanaka H et al. Homeostasis model assessment as a clinical index of insulin resistance. Diabetes Care 1999; 22: 1911-1912.
25. Hermans M, Levy J, Morris R, Turner R. Comparison of tests of β-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999; 48: 1779-1786.
26. Svennerholm L, Fredman P. A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta 1980; 617: 97-109.
27. Fredman P, Månsson J-E, Bigner SH, Wikstrand CJ, Bigner DD, Svennerholm L. Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats. Biochim Biophys Acta 1990; 1045: 239-244.
28. Östgren CJ, Lindblad U, Melander A, Råstam L. Survival in patients with type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabetes Care 2002; 25: 1297-1302.
29. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
30. Buschard K, Diamant M, Bovin LF, Fredman P, Bendtzen K. sulfatide and its precursor, galacto-sylceramide, influence the production of cytokines in human mononuclear cells. APMIS 1996; 104: 938-944.
31. Winkler G, Salamon F, Harmos G, Salamon D, Speer G, Szekeres O et al. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. Diabetes Res Clin Prac 1998; 42: 169-174.
32. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
33. Bovin LF, Fredman P, Mansson JE, Buschard K, Bendtzen K. In vitro production of cytokines is influenced by sulfatide and its precursor galactosylceramide. FEBS Lett 1999; 455: 339-343.
34. Yamada K, Tojo SJ, Hayashi M, Morooka S. The role of P-selectin, sialyl Lewis X and sulfatide in myocardial ischemia and reperfusion injury. Eur J Pharmacol 1998; 346: 217-225.